| 产品描述： | Anavex 2-73 is a Sigma-1 Receptor agonist (IC50: 860 nM) |
| 靶点： |
Sigma receptor;Sigmareceptor |
| 体内研究： |
The pretreatment of Anavex 2-73 (1/3 mg/kg) dose-dependently reduces the scopolamine-induced alternation deficit. The pretreatment with Anavex 2-73 (>0.3 mg/kg) dose-dependently and significantly attenuates the impairments of step-through latency. The Anavex 2-73 (1mg/kg) dose-dependently blocks the recognition memory deficit. One day after injections, the significant Aβ25-35-induced decrease in Akt phosphorylation is significantly attenuated by Anavex 2-73 (0.1/1mg/kg). Seven days after injections, Anavex 2-73 attenuates the decrease in Ser9 phosphorylation induced by the peptide (0.3/1mg/kg) |
| 动物实验： |
Drugs (including Anavex 2-73) are solubilized in physiological saline at the concentration of 5mg/mL.Male mice aged 7-9 weeks and weighing 32±2?g are used. Drugs (including Anavex 2-73) are brought up to each dose by dilution and injected in a volume of 100μL/20g body weight. Animals are used between days 1 and 9 after i.c.v. injections for behavioral testing or killed before biochemical measures. |
| 参考文献： |
1. Valentine Lahmy, et al. Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic andσ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease. Neuropsychopharmacology. 2013 Aug; 38(9): 1706-1723. 2. Villard V, et al. Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative. J Psychopharmacol. 2011 Aug;25(8):1101-17. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.146 ml |
15.731 ml |
31.461 ml |
| 5 mM |
0.629 ml |
3.146 ml |
6.292 ml |
| 10 mM |
0.315 ml |
1.573 ml |
3.146 ml |
| 50 mM |
0.063 ml |
0.315 ml |
0.629 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京